Home
About
Overview
Sharing Data
ORCID
Help
History (18)
Sericins
Novel drug targets in acute leukemia.
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
See All 18 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses. Cancer Cell. 2014 Jan 13; 25(1):37-48.
View in:
PubMed
subject areas
Adaptive Immunity
Animals
Antibodies
B7-H1 Antigen
Cell Line, Tumor
Cross-Priming
Dendritic Cells
Enzyme-Linked Immunosorbent Assay
ErbB Receptors
Flow Cytometry
Immunity, Innate
Immunotherapy
Interferon-beta
Lymphocyte Activation
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Transgenic
Neoplasms, Experimental
Tumor Microenvironment
authors with profiles
Ralph Weichselbaum
Thomas Gajewski